Stay updated on Pembrolizumab & Cetuximab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.

Latest updates to the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4 on the page, indicating a minor version update. The content and study details remain unchanged.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check31 days agoChange DetectedThe page’s displayed site/version label has been updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a minor maintenance or deployment change with no change to the underlying study information.SummaryDifference0.0%

- Check38 days agoChange DetectedRevision tag updated to v3.5.2.SummaryDifference0.0%

- Check52 days agoChange DetectedThe study’s Conditions list now includes squamous cell carcinoma of the head and neck and nasal cavity/paranasal sinus carcinoma.SummaryDifference0.1%

- Check67 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check74 days agoChange Detected- Revision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab & Cetuximab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Cetuximab in HNSCC Clinical Trial page.